Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Masitinib plus Gemcitabine in Advanced Ovarian Cancer
NCT02490488Phase 3Completed
- Sponsor
- AB Science
- Start
- Apr 2014
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 3 trial of masitinib in epithelial ovarian cancer (EOC), sponsored by AB Science. Started Apr 2014; status: completed.
02
Drugs
masitinib
03
Conditions
epithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on NCT02490488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02490488.